← Patent Expiry Watch
October 15, 2026 · Patent expires November 10, 2031
Ubrelvy (Ubrogepant): The 2031-2035 Generic Opportunity Window
AbbVie's oral CGRP receptor antagonist Ubrelvy (ubrogepant) crossed $1.0B in 2024 global revenues while remaining 100% brand-only in the US today. Core substance patent US 9,499,545 expires on November 10, 2031, with secondary solid dispersion formulation patents extending protection to January 30, 2035 and method patents to 2041. Generic challengers including Zydus Lifesciences (holding FDA tentative approval ANDA 218662), Aurobindo Pharma, Hetero Labs, and MSN Laboratories are actively positioned for the 2031-2035 generic opportunity window.
What we do
We track expirations like this continuously
This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.